In a mouse model of intraosseous prostate cancer, CCL2 signaling was blocked using neutralizing anti-CCL2 antibodies alone or in combination with the chemotherapeutic drug docetaxel; the results indicated that CCL2 blockade inhibits prostate cancer development and the effect is more profound when combined with docetaxel (Kirk et al., 2013). This evidence concerns the gene CCL2 and Familial prostate cancer.